‘Triple-G’ weight loss drug update: Even on the lowest dose, trial patients lost 12.7% of their weight

The drug, the first of its kind to target three metabolic receptors (GLP-1, GIP, and glucagon), is nearing the end of clinical trials and is expected to be submitted to the FDA…

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (nypost.com)